I. EDITORIAL POLICY

The Journal of Nuclear Medicine publishes material of interest to the practitioners and scientists in the broad field of nuclear medicine. Proffered articles describing original laboratory or clinical investigations, case reports, technical notes and letters to the editor will be considered for publication. From time invited articles, editorials, and reviews of selected topics will be published. Manuscripts, including illustrations and tables, must be original and not under consideration by another publication.

The Journal of Nuclear Medicine has agreed to receive manuscripts in accordance with the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals," as cited in the following sources: Ann Intern Med (1988; 108:258–265) and Br Med J (1988; 296:401–405). In preparing manuscripts, authors should follow the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals," and specific author instructions detailed below. Also, helpful guidance in conforming to the "Uniform Requirements" may be found in Medical Style & Format: An International Manual for Authors, Editors, and Publishers by Edward J. Huth, MD (Philadelphia: ISI Press; 1987).

II. MANUSCRIPT SUBMISSION

Submit one original and three copies of the manuscript and four copies of the figures to:

H. William Strauss, MD, Editor-in-Chief The Journal of Nuclear Medicine Room 5406, MGH-East Building 149, Thirteenth Street, Charlestown, MA 02129.

The editorial office phone number is (617)726-5785. Original manuscripts will not be accepted by facsimile, but for other communications the fax number is (617)726-5708.

All manuscripts should be accompanied by a covering letter from the author responsible for correspondence regarding the manuscript. The covering letter should contain the following copyright disclosure statement in compliance with the Copyright Revision Act of 1976, effective January 1, 1978.

Upon acceptance by The Journal of Nuclear Medicine, all copyright ownership for the article is transferred to The Society of Nuclear Medicine. We, the undersigned co-authors of this article, have contributed significantly to and share in the responsibility for the release of any part or all of the material contained within the article noted above. The undersigned stipulate that the material submitted to The Journal of Nuclear Medicine is new, original and has not been submitted to another publication for concurrent consideration.

We also attest that any human and/or animal studies undertaken as part of the research from which this manuscript was derived are in compliance with regulations of our institution(s) and with generally accepted guidelines governing such work.

We further attest that we have herein disclosed any and all financial or other relationships which could be construed as a conflict of interest, and that all sources of financial support for this study have been disclosed and are indicated in the acknowledgement.

This statement must be signed by all of the listed co-authors.

Copyright requirement does not apply to work prepared by United States government employees as part of their official duties.

The covering letter should also contain a statement that the manuscript has been seen and approved by all authors and should give any additional information which may be helpful to the Editor. If there has been any prior publication of any part of the work, this should be acknowledged and appropriate written permission included. If color illustrations are included, a statement that the author(s) is (are) willing to assume the cost of color separation and reproduction is requested.

You may suggest individuals who could serve as reviewers for your manuscript.

III. REVIEW PROCEDURE

Submitted manuscripts are reviewed for originality, significance, adequacy of documentation, reader interest, and composition.

Manuscripts not submitted according to author instructions will be returned to the author for correction prior to beginning the peer review process.

All manuscripts considered suitable for review are evaluated by a minimum of two reviewers. It is unusual for a manuscript to be accepted for publication without first undergoing a process of revision. Revised manuscripts are judged on the adequacy of responses to suggestions and criticisms made during the initial review. Reviewers for the *Journal* may seek assistance from sources within their institution when reviewing manuscripts, but the data reported in submitted manuscripts must be kept confidential at all times.

All accepted manuscripts are subject to editing for scientific accuracy, clarity and style.

IV. FORMAT REQUIREMENTS

A. General Requirements

Manuscripts must be written in English. When necessary, authors should seek the assistance of experienced, English-speaking medical editors. A medical editor should review the final draft of the original and any revisions of the manuscript.

Type the manuscript on white bond paper, $8\% \times 11$ in. $(21.6 \times 27.9$ cm), with margins of at least 1% in. (4 cm). Type on one side of the paper only, double spacing every page. Begin each of the following sections on separate pages and in the following order: title page, abstract, text, acknowledgments, references, tables (each on a separate page), and legends. Number pages consecutively, beginning with the title page. Type the name of the senior author and page number in the upper right-hand corner of each page.

B. Title Page

The title page of the manuscript should include: (1) concise and informative title (fewer than 200 characters); (2) short running head or footline of no more than 40 characters (letters and spaces) placed at the bottom of the title page and identified; (3) complete byline, with first name, middle initial, and last name of each author and highest academic degree(s), up to ten authors may be cited; (4) complete affiliation for each author, with the name of department(s) and institution(s) to which the work should be attributed; (5) disclaimer, if any; (6) name, address, and telephone number of one author responsible for correspondence about the manuscript; and (7) name and address of author to whom reprint requests should be directed, or statement that reprints are not available from the author. Financial support for the work should be noted in a statement on this page.

C. Abstract

A structured abstract must be included with each original scientific manuscript submitted to the *Journal*. The abstract should contain a maximum of 350 words and include four clearly identifiable elements of content: rationale (goals of the investigation), methods (description of study subjects or experiments, animals and observational and analytical techniques), major findings, and principle conclusions. These sections should not be preceded by headings or placed in separate paragraphs.

D. Text

-Presentation

Generic names should be used throughout the text. Identify instruments and radiopharmaceuticals by manufacturer name and address in parentheses and describe procedures in sufficient detail to allow other investigators to reproduce the results.

The text of **original scientific** and **methodology articles** is usually divided into the following sections: Introduction, Materials and Methods, Results, Discussion, and Summary or Conclusion. The text of original, scientific papers, exclusive of the abstract, legends, tables and references, should not exceed 5000 words.

Case Reports should contain a concise description of no more than 1250 words, exclusive of the abstract, legends, tables and references, illustrated with no more than three figures, emphasizing the nuclear medicine aspects and including methodology, data, and correlative studies.

Letters should concern previously published material or matters of general interest and should be brief and to the point. All material is subject to editing. Letters commenting on previously published articles should be received within one year of the date of the referenced article's publication. Letters should contain no more than 10 references.

Journal policy prohibits the use of hyperbolic terms or phrases in the title, abstract, or body of the text of submitted manuscripts. Qualitative claims as to the superiority (superior, best...), primacy (first, novel, unique) or per-

Information for Authors 31A

Information for Authors

formance of an idea or instrument should be omitted.

-References

References should be cited in consecutive numerical order at first mention in the text and designated by the reference number underlined and in parentheses. References appearing in a table or figure should be numbered sequentially with those in the text.

The Reference list must be typed double-spaced and numbered consecutively, as in the text. The *Journal* follows *Index Medicus* style for references and abbreviates journal names according to the *List of Journals Indexed in Index Medicus*. "Unpublished observations" and "personal communications" should not be used as references, although written—not verbal—communications may be noted as such in the text. References cited as "in press" must have been accepted and not merely in preparation or submitted. The author is responsible for the accuracy of all references and must verify them against the original document.

For journal articles, list all authors when six or less; for seven or more authors, list the first three followed by et al.:

Baumier PL, Krohn KA, Carrasquillo JA, et al. Melanoma localization in nude mice with monoclonal Fab against p97. *J Nucl Med* 1985; 26:1172–1179.

Weissmann HS, Badia J, Sugarman LA, Kluger L, Rosenblatt R, Freeman LM. Spectrum of **Tc-IDA cholescintigraphic patterns in acute cholecystitis. *Radiology* 1981; 138:167–175.

For books and book chapters, follow the examples below:

DeGroot LJ. Evaluation of thyroid function and thyroid disease. In: DeGroot LJ, Stanbury JB, eds. *The thyroid and its diseases*, 4th edition. New York: Wiley; 1975:196–248.

Dupont B. Bone marrow transplantation in severe combined immunodeficiency with an unrelated MLC compatible donor. In:White HJ, Smith R, eds. *Proceedings of the third annual meeting of the International Society of Experimental Hematology*. Houston: International Society for Experimental Hematology; 1974:44–46.

-Units of Measurement

All measurements should be listed in SI units. Older conventions may be used after the SI units but should be placed in parentheses.

-Abbreviations and Symbols

With the exception of units of measurement, the *Journal* discourages the use of abbreviations. For additional information on proper medical abbreviations, consult the *CBE Style Manual*, Fifth Edition (Bethesda, MD: Council of Biology Editors, 1983). When an abbreviation is used, it should be preceded by the full word or name of the item being abbreviated.

E. Figures

-Tables

Type each table double-spaced on a separate page. Do not submit tables as photographs.

Tables should be self-explanatory and should supplement, not duplicate, the text. Each table must be cited in consecutive numerical order in the text. Number the tables consecutively with an arabic number following the word "TABLE". The titles should be descriptive, brief, and typed centered in upper-and lower-case letters. Place horizontal rules below the title, column headings, and at the end of the table. Do not use vertical lines. Give each column a short or abbreviated heading.

Place explanatory matter in footnotes, not in the heading. Use the following symbols, in this sequence: *, †, ‡, §, ¶, **. Expand in the footnote all nonstandard abbreviations used in each table. For footnotes, identify statistical measures of variations, such as standard deviation and standard error of the mean. If data from another published source are used, obtain written permission from the publisher of the original source and acknowledge fully. If data from an unpublished source are used, obtain permission from the principal investigator and acknowledge fully.

-Illustrations

Illustrations should clarify and augment the text. Because imaging is a major aspect of nuclear medicine, the selection of sharp, high-quality illustrations is of paramount importance. Figures of inferior quality will be returned to the author for correction or replacement.

Submit four complete sets of glossy illustrations, no smaller than $3\% \times 5$ in. nor larger than 8×10 in. Do not send original artwork. Glossy photographs of line drawings rendered professionally on white drawing paper in black India ink, with template or typeset lettering, should be submitted. No hand-drawn or typewritten art will be accepted. Letters, numbers, and symbols (typeset or template) must be clear and of sufficient size to retain legibility after reduction.

Each illustration must be numbered and cited in consecutive order in the text. Illustrations should be identified on a gummed label affixed to the back of each illustration and contain the following information: figure number, part of figure (if more than one), senior author's name, and designation of "top."

Color illustrations will be considered for publication, but the author is responsible for all charges relating to separations and printing. An estimate of these charges will be sent to the author at the time of production. Author approval of charges is required before production will continue. Four complete sets of glossy color photographs (not transparencies) must be submitted for review. Polaroid prints are not acceptable. All submitted illustrations become the property of The Society of Nuclear Medicine and will not be returned unless the manuscript is rejected.

-Legends for Illustrations

Legends for illustrations should be concise and should not repeat the text. Legends should be typed double-spaced on a separate page. Each figure should be cited in consecutive numerical order in the text. Number the figures with an arabic number following the word "FIGURE". Use letters to designate parts of illustrations (e.g., A, B, C) and describe each part clearly in the legend. Any letter designations or arrows appearing on the illustration should be identified and described fully.

Original (not previously published) illustrations are preferred for publication in the *Journal*; however, if illustrations have been published previously, authors are responsible for obtaining written permission from the publisher to reprint. The source of the original material must be cited in the references and the following credit line in parenthesis included in the legend: "Reprinted by permission of Ref. X." All permission releases must be submitted to the Editor at the time of manuscript submission.

F. Acknowledgments

Acknowledge persons or agencies contributing substantially to the work, including any grant support.

V. MANUSCRIPT CHECKLIST

| Original double-spaced typed manuscript and three copies. |
|---|
| _ Four sets of unmounted glossy Figures (no smaller than $3\% \times 5$ in. nor larger than 8×10 in.). |
| _ Copyright transfer. |
| _ Title page with title, authors' names, and complete affiliations; corresponding author, complete address, and telephone number; author for reprint requests and complete address. |
| _ Structured abstract (maximum, 350 words). |
| References in consecutive numerical order. Reference list typed double-spaced. |
| _ Figures and Tables in consecutive numerical order. |
| _ Legends for all Figures; typed double-spaced. |
| Consent forms for patient photographs. |
| Written permission from the publisher to reprint previously published Figures and Tables. |

TUESDAY, JUNE 8/EXHIBIT HALL OPEN 10:00-5:00, POSTERS AND SCIENTIFIC EXHIBITS OPEN 10:00-7:00

Formal Opening and Plenary Session: Nuclear Medicine Pioneer Award RECIPIENT: C. Craig Harris, MS PRESENTER: R. Edward Coleman, MD Tenth Annual SNM Lectureship: H. William Strauss, MD. Rooms 105&106 Followed by the Grand Opening of the Exposition.

Coffee break in the EXHIBIT HALL, Sponsored by McNeil Pharmaceutical

| 10:30 | | THE PROPERTY OF THE PARTY OF TH | The second of th | of monominations | | | | | | |
|---------------|--|--|--|--|--|--|---|--|--|-----------|
| | Room 105 | Room 106 | Room 107 | Rooms 104 C&D | Rooms 104 A&B | Rooms 103 A&B | Room 203 | Room 202B | Room 202D | Room 201D |
| 10:30- | SPECT INSTRUMEN- TATION: Current Status | BONE SPECT IMAGING | CARDIOVASCULAR: Young Investigator Award Competition | NEUROLOGY CLINI- CAL I: Dementia I | ONCOLOGY/NON- Antibody i | RADIOPHARMACEUTI- CAL CHEMISTRY: Positions I: Brain Agents | INSTRUMENTATION & DATA ANALYSIS: SPECT I: SPECT Systems/Collimation | GASTROENTEROLOGY I: GI Motility | ENDOCRINOLOGY I: Thyroid/ Pheochromocytoma | |
| | | | Session 1 | Session 2 | Session 3 | Session 4 | Session 5 | Session 6 | Session 7 | |
| 1:30 | Visit Exhibits and | Visit Exhibits and have Lunch in the EXHIBIT HALL | e EXHIBIT HALL | ACADEMIC COUNCIL ANNUAL PROGRAM: Who Should Train Tomorrow's Nuclear Physician? | | | | | | |
| 3:00 | CARDIOVASCULAR: Update on Role of Nuclear Techniques for Detection of CAD | METHODOLOGY FOR RENAL FUNCTION AND STUDIES | CARDIOVASCULAR CLINICAL: Antimyosin/MIBG Session 8 | CARDIOVASCULAR BASIC: Perfusion and Metabolism Session 9 | PULMONARY I: Thromboembolism Session 10 | RADIOPHARMACEUTI- CAL CHEMISTRY: Technetium 1 Session 11 | INSTRUMENTATION & DATA ANALYSIS: SPECT II: Reconstruction Methods Session 12 | ONCOLOGY/NON- ANTIBODY II Session 13 | CAL II: Epilepsy Session 14 | |
| 3:30 | | Visit Exhibits in the EXHIBIT HALL | | | | | | | | |
| 3:30- 5:00 | BRAIN IMAGING: An Introduction to Instrumentation | CORRELATIVE IMAG- ING IN ABDOMINAL DISORDERS | CARDIOVASCULAR CLINICAL/PET: Myocardial Viability: Single Photon and PET Approaches Session 15 | NEW Ligands New Ligands Session 16 | COMPUTER AND INSTRUMENTATION YOUNG INVESTIGA- TOR'S SYMPOSIUM Session 17 | RADIOPHARMACEUTI- CAL CHEMISTRY: Proteins/Antibodies I Session 18 | INSTRUMENTATION & DATA ANALYSIS: SPECT III: Cardiac SPECT/Attenuation Compensation Methods Session 19 | NEUROLOGY CLINI- CAL III: Movement Disorders Session 20 | BONE & JOINT I: Tumor Session 21 | |
| 5:00- | | Awards, SNM Busi | Presentation of Awards, SNM Business Meeting, and Wine and Cheese Reception • Rooms 104C&D | Wine and Cheese | Reception • Roor | ns 104C&D | | | | |

The Nuclear Medicine Review Course will be held Tuesday - Friday at the Toronto Convention Centre in Room 101.

| | | WEDNESI | WEDNESDAY, JUNE 9/EXHIBIT HALL OPEN 10:00-5:00, POSTERS AND SCIENTIFIC EXHIBITS 7:00-7:00 | HIBIT HALL OP | EN 10:00-5:00 | , POSTERS ANI | O SCIENTIFIC E | XHIBITS 7:00- | 7:00 | |
|--------|--|---|---|--|--|--|--|--|--------------------------------|--------------------------------------|
| | Room 105 | Room 106 | Room 107 | Rooms 104 C&D | Rooms 104 A&B | Rooms 103 A&B Room 203 | NAME OF THE OWNER. | Room 202B | Room 202D | Room 201D |
| 8:30- | GASTROENTEROLOGY: Quantitative | CARDIOVASCULAR: Pharmacologic Stress | CARDIOVASCULAR CLINICAL: Left | CARDIOVASCULAR PET: Clinical Muccardial Blood Flow | NEUROLOGY CLINI- CAL IV: Brain Tumors | CAL CHEMISTRY: | INSTRUMENTATION & ENDATA ANALYSIS: PET: Se | ENDOCRINOLOGY II: PULMONARY II: Somatostatin, etc. Miscellaneous | PULMONARY II: Miscellaneous | SPECT BRAIN IMAG- ING PRACTICUM I |
| | Groteseringraphy | 25. LAGICISC | Session 22 | Session 23 | Session 24 | Session 25 | Session 26 | Session 27 | Session 28 | |
| 0:00- | Coffee break in the EXHIBIT HALL, Sponsored by McNeil Pharmaceutical | ak in the EXHIBIT | HALL, Sponsored | by McNeil Pharm | aceutical | | | | | |
| 10:30- | THERAPY OF THE PAIN BONE IMAGING IN | BONE IMAGING IN | | | | THE PLANT OF THE P | 14 -11 11010010 | Home | | |

| ### ### ### ### ### ### ### ### ### ## | 10:00- | - | TIGING CYUIDI | Session 22 | Session 23 | Session 24 | Session 25 | Session 26 | Session 27 | Session 28 | |
|--|-----------------|------|---|------------------|---|---|--|---|--|--|--|
| THERAPY OF THE PAIN BONE IMAGING IN OF THE PAIN BONE IMAGING IN CHARACTERS SESSION I in the EXHIBIT HALL WISEALED SOUNCES. VISIT EXHIbits and have Lunch in the EXHIBIT HALL CARDIOVASCULAR Prognosis in Coronary MEDICINE IN AIDS Artery Disease DERS Session 29 Session 30 Session 31 Session 32 Session 32 Session 33 Session 34 Session 36 Session 36 Session 37 Session 37 Session 38 Session 38 Session 38 Session 38 Session 39 Session 40 Session 39 Session 39 Session 40 Session 40 Session 39 Session 39 Session 40 Session 40 Session 40 Session 39 Session 40 Sessi | 10:30 | • | eak III IIIe EANIDII | narr, spollsoled | Dy menell rilarii | laceuncai | | | | | |
| Visit Exhibits and have Lunch in the EXHIBIT HALL CARDIOVASCULAR: ROLE OF NUCLEAR CARDIOVASCULAR Prognosis in Coronary Artery Disease DERS in Coronary DERS in Coronary DERS in Coronary DERS in Coronary Artery Disease DERS Artery Disease DERS Artery Disease DERS Artery Disease DERS in Coronary Artery Disease DERS Artery Disease DERS Artery Disease DERS Innervation, Viability DERS in Coronary Artery Disease DERS Artery Disease DERS Innervation DERS Innervation DERS Innervation Session 30 Session 31 Session 32 Session 32 Session 34 Session 34 Session 34 Session 35 Southeastern Chapter Ders Ders Ders Ders Ders Ders Ders De | 10:30- 12:00 | FOZJ | BONE IMAGING IN ORTHOPEDICS AND SPORTS MEDICINE | | | "MEET THE | AUTHOR" POSTER | SESSION I in the | EXHIBIT HALL | | |
| CARDIDVASCULAR: Prognosis in Coronary MEDICINE IN AIDS Artery Disease Begistribution- Bers CLINICAL: Thallium Session 29 Session 30 Session 30 Session 37 Session 37 Session 37 Session 37 Session 38 Session 38 Session 39 Session 30 S | 12:00 | | d have Lunch in the | e EXHIBIT HALL | | | | | | | |
| Visit Exhibits in the EXHIBIT HALL MONOCLONAL ANTI- BODIEs: Current Status I Lakes Challenges Session 36 Session 37 Session 38 Session 37 Session 38 Session 37 Session 38 Session 37 Session 37 Session 37 Session 37 Session 37 Session 38 Sess | 3:00 | | ROLE OF NUCLEAR MEDICINE IN AIDS AND RELATED DISOR- DERS | | CARDIOVASCULAR BASIC: Receptors, Innervation, Viability | PSYCHIATRY I: Mood Disorders | RADIOPHARMACEUTI- CAL CHEMISTRY: Pre- Clinical Testing I | | PEDIATRICS I: SPECT/Tumor | ONCOLOGY/ANTI- BODY I: Radioimmunotherapy: Clinical | 1:00-2:30 SPECT BRAIN IMAG- ING PRACTICUM II |
| Visit Exhibits in the EXHIBIT HALL MONOCLONAL ANTI- GHAPTER BOWL CHAL- BODIES: Current Status LENGE: Eastern Great CLINICAL: Blumgar Southeastern Chapter Southeastern Chapter Session 36 Visit Exhibits in the EXHIBIT HALL REPLIEMISTRY: BODY III REPLIEMISTRY III REPLIEMISTR | | | | Session 29 | Session 30 | Session 31 | Session 32 | Session 33 | Session 34 | Session 35 | |
| MONOCLONAL ANTI- CHAPTER BOWL CHAL- BODIES: Current Status LectureApplications of Immunoscintigraphy Lakes Challenges Southeastern Chapter Session 36 Session 37 CHAPTER BOWL CHAL- CAL CHEMISTRY: BODY III Activation Studies CLUCHEMISTRY: BODY III Activation Studies CLUCHEMISTRY BODY III | 3:30 | | the EXHIBIT HALL | | | | | | | | |
| Session 37 Session 38 Session 39 Session 40 Session 41 | 3:30- 5:00 | | | | | NEUROLOGY BASIC II: Activation Studies | RADIOPHARMACEUTI- CAL CHEMISTRY: Proteins/Antibodies II | INSTRUMENTATION & DATA ANALYSIS: GEN- ERAL I: Monte Carlo Simulations, Scatter and Attenuation Correction | HEMATOLOGY/INFEC- TIOUS DISEASE I: Infection: Clinical | NEUROLOGY CLINICAL V: Cerebrovascular Disease I | SPECT BRAIN IMAGING PRACTICUM III |
| | | | | Session 36 | Session 37 | Session 38 | Session 39 | Session 40 | Session 41 | Session 42 | |

THURSDAY, JUNE 10/ EXHIBIT HALL OPEN 10:00-5:00, POSTERS AND SCIENTIFIC EXHIBITS OPEN 7:00-7:00

| | R00III 103 | | 100111001 | | | | | | | |
|---------------|--|---|---|--|--|--|---|--|---|---|
| 88 | GASTROENTEROLOGY: Gastric Emptying, Inflammatory Bowel Disease and Liver Transplants | NEW DEVELOPMENTS IN PEDIATRIC IMAGING | CARDIOVASCULAR CLINICAL: Dual Isotope Myocardial Perfusion Imaging Session 43 | CARDIOVASCULAR BASIC: Antibodies, Peptides, and Proteins Session 44 | PSYCHIATRY II: Studies in Normals Session 45 | RADIOPHARMACEUTI- CAL CHEMISTRY: Positrons II: Precursor Production Session 46 | INSTRUMENTATION & DATA ANALYSIS: PET: Analysis III Session 47 | INSTRUMENTATION & DATA ANALYSIS: SPECT IV. Attenuation and Scatter Compensation Methods Session 48 | ONCOLOGY/NON- ANTIBODY IV Session 49 | SPECT BRAIN IMAG- ING PRACTICUM IV |
| 10:00- | | t in the EXHIBIT H | Coffee break in the EXHIBIT HALL, Sponsored by McNeil Pharm | y McNeil Pharmat | aceutical | | | | | |
| 10:30- | MONOCLONAL ANTI- BODIES: Radioimmunotherapy | LABORATORY AUTO- MATION FOR RADIO- PHARMACEUTICALS | | | "MEET THE A | UTHOR" POSTER | "MEET THE AUTHOR" POSTER SESSION II in the EXHIBIT HALL | EXHIBIT HALL | | |
| 12:00- | Visit Exhibits and | Visit Exhibits and have Lunch in the EXHIBIT HALL | EXHIBIT HALL | | | | | | | |
| 1:30- 3:00 | INTERVENTIONAL STUDIES IN RENAL NUCLEAR MEDICINE | RADIOPHARMACEUTI- CAL SCIENCE: Regulatory Affairs Update | CARDIOVASCULAR CLINICAL: Myocardial Perfusion Imaging and Prognosis I Session 50 | GASTROENTEROLOGY II: CCK Gallbladder Session 51 | PSYCHIATRY III: Schizophrenia/Autism, etc. Session 52 | RADIOPHARMACEUTI- CAL CHEMISTRY: Positrons III: Heart and Peripheral Agents Session 53 | INSTRUMENTATION & DATA ANALYSIS: SPECT V: Converging- Beam Tomography Session 54 | ONCOL OGY/ANTIBODY II: GI/GYN Cancer Imaging Session 55 | BONE & JOINT II: Infection Session 56 | 1:00-2:30 SPECT BRAIN IMAG- ING PRACTICUM V |
| 3:30 | Visit Exhibits in the EXHIBIT HALL | he EXHIBIT HALL | | | | | | | | |
| 5:00 | SCINTIGRAPHIC DIAGNOSIS OF OSTEOMYELITIS | CORRELATIVE IMAG- ING: Functional and Structural Imaging of the Thyroids and Parathyroids | CARDIOVASCULAR CLINICAL: Myocardial Perfusion imaging and Prognosis II Session 57 | CARDIOVASCULAR PET: Basic Studies in Myocardial Blood Flow Session 58 | RENALHYPERTEN- SION I: Quantitation/PET Session 59 | RADIOPHARMACEUTI- CAL CHEMISTRY: Halogens Session 60 | INSTRUMENTATION & DATA ANALYSIS: SPECT VI: Motion Correction/ Functional Imaging Session 61 | NEUROLOGY CLINI- CAL VI: Cerebrovascular Disease II Session 62 | ONCOLOGY/ANTIBODY III: New Approaches in Radioimmunotherapy and Antibody Imaging Session 63 | SPECT BRAIN IMAG- ING PRACTICUM VI |
| I | | | 0 10000 | 20 1101000 | 00 100000 | 20 11010000 | 0 10000 | 1010000 | 200000 | |

FRIDAY, JUNE 11/EXHIBIT HALL OPEN 8:30-12:00, POSTERS AND SCIENTIFIC EXHIBITS 7:00-12:00

| 8:00- | | 20111001 | ROOM 107 | Rooms 104 C&D | Rooms 104 A&B | Hooms 103 A&B | Room 203 | Koom 202B | Hoom 202D | Room 206D |
|--------|--|---|---|--|---|--|---|--|--|---|
| _ | RADIONUCLIDE MONI- Toring of Organ Transplants | MONOCLONAL ANTI- BODIES: Molecular Biology in Nuclear Medicine | CARDIOVASCULAR CLINICAL: Pharma- cologic Stress | CARDIOVASCULAR BASIC: Gated Myocar- dial/Blood Pool Scinti- graphy | GASTROENTEROLOGY III: GI Tumors | RADIOPHARMACEUTI- CAL CHEMISTRY: Proteins/Antibodies III | INSTRUMENTATION & DATA ANALYSIS: PET: Instrumentation | NEUROLOGY CLINI- CAL VII: Miscellaneous | HEMATOLOGY/INFEC- TIOUS DISEASE II: Infection: Pre-Clinical | DOSIMETRY/RADIO- BIOLOGY I: Novel Dosimetry Consider- ations for Therapy |
| | | | Session 64 | Session 65 | Session 66 | Session 67 | Session 68 | Session 69 | Session 70 | Session 71 |
| 9:30- | Coffee Brea | k in the EXHIBIT H | IALL, Sponsored t | Coffee Break in the EXHIBIT HALL, Sponsored by McNeil Pharmaceutical | ceutical | | | | | |
| | CARDIOVASCULAR: Practical Issues in Nuclear Cardiac Imaging | RENAL: Clearance and Imaging Techniques | CARDIOVASCULAR PET: Metabolic Imaging | NEUROLOGY BASIC III: Receptor Quantitation | BONE & JOINT III: Miscellaneous | GASTROENTEROLOGY IV: Liver | INSTRUMENTATION & DATA ANALYSIS: GEN-ERAL II: Detectors, Data Acquisition and Pro- | ONCOLOGY/ANTIBODY IV: Targeting/ Miscellaneous | NEUROLOGY CLINI- CAL VIII: Dementia II | PEDIATRICS II: Genitourinary |
| | | | Session 72 | Session 73 | Session 74 | Session 75 | cessing Session 76 | Session 77 | Session 78 | Session 79 |
| 11:30- | MID-DAY BREAK | | | | | | | | | |
| 1:30 | | CHERNOBYL: Radiation Effects: An Update on A-Bomb Survivors, Chemobyl, | HEMATOLOGY/INFEC- TIOUS DISEASE III: Specific Imaging and Hematology | CARDIOVASCULAR CLINICAL: Technetium-99m Perfusion Agents I | PULMONARY III: Thromboembolism | RADIOPHARMACEUTI- CAL CHEMISTRY: Pre- Clinical Testing II | INSTRUMENTATION & DATA ANALYSIS: GEN- ERAL III: Multimodality Display, Motion | RADIOASSAY: Berson Yalow Award Paper | DOSIMETRY/RADIOBI- OLOGY II: Treatment Planning in Radioimmunotherapy | RENAL/HYPERTEN- Sion II: Miscellaneous |
| | | and Radon Studies | Session 80 | Session 81 | Session 82 | Session 83 | Correction Session 84 | Session 85 | Session 86 | Session 87 |
| 1:30- | BREAK | | | | | | | | | |
| | SPECT ANALYSIS: Current Status | CARDIOVASCULAR: Nuclear Cardiac Imaging Debate | CLINICAL: Technetium- 99m Perfusion Agents | NEUROLOGY BASIC IV: Dopaminergic | OLOGY III: Radiobiology of Incorporated | RADIOPHARMACEUTI- CAL CHEMISTRY: Technetium II | INSTRUMENTATION & DATA ANALYSIS: PET: Instrumentation II | RENAL/HYPERTEN- SION III: SPECT/Miscellaneous | ONCOLOGY/NON- ANTIBODY V | |
| | | | II. Unique Applications Session 88 | Session 89 | Session 90 | Session 91 | Session 92 | Session 93 | Session 94 | |
| 3:30- | | Scientific Meeting Highlights Henry N. Wagner, Jr., MD | The P | The Nuclear Medicine | Review Course w | ie Review Course will be held Tuesday - Friday at the Toronto Convention Centre in Room 101. | ıy - Friday at the 1 | Foronto Conventio | n Centre in Room | 101. |

| MANAGING QUALITY SERVICE CATEGORICAL • Room 202B 8:00-3:00 7:30-9:30 Opening Cocktail Reception at the Sheraton Centre Hotel & Towers | | Room 206D | Room 2068 | IECHNOLOGIST SECTION MAIRIX Room 205D | Room 206F | Room 2058 | |
|---|-----------|--------------------------------------|---------------------------------|--|-----------|-----------|--|
| 7:30-9:30 Opening Cocktail Reception at the Sheraton Centre Hotel & Towers | 3:00-3:00 | MANAGING QUALITY SERVICE CATEGORICAL | • Room 202B | TEACHING AND EVALUATING STUDENTS IN THE AFFECTIVE DOMAIN | | | |
| | 7:30-9:30 | Opening Cocktail Reception at t | he Sheraton Centre Hotel & Towe | 2 | | | |

| N. ST. ST. | Коот 206D | Room 206B | Room 205D | Room 206F | Room 205B |
|-----------------------|---|---|--|--|---|
| JUNE 7 8:00-3:00 | MANAGING QUALITY SERVICE CATEGORICAL • Room 2028 | • Room 202B | TEACHING AND EVALUATING STUDENTS IN THE AFFECTIVE DOMAIN | | |
| 7:30-9:30 | Opening Cocktail Reception at the Sheraton Centre Hot | ie Sheraton Centre Hotel & Towers | rs | | |
| JUNE 8 7:30-8:30 | First Time Participant to SNM Breakfast and Orientation • Room 204 | Orientation • Room 204 | | | |
| 8:15-10:00 | | Formal Opening and Plenary Session Rooms 105&106, Followed by the Grand Opening of the Exposition | ie Exposition | | |
| 10:00-10:30 | Coffee break in the EXHIBIT HALL, Sponsored by MCNei | ALL, Sponsored by McNeil Pharmaceutical | eutical | | |
| 10:30-12:00 | ORTHOPEDIC IMAGING IN THE EVALUATION OF THE BENIGN BONE DISEASE, INFECTION AND METASTASES I | SPECT I: Establishing a SPECT Practice | CURRENT ISSUES IN QUALITY ASSURANCE- MEETING THE REGULATIONS I | Scientific Papers: Cardiovascular Technologist Investigator Competition | 10:30-1:30 Student day |
| 12:00-1:30 | Visit Exhibits and have lunch in the EXHIBIT HALL | the EXHIBIT HALL | | | |
| 1:30-3:00 | ORTHOPEDIC IMAGING II | SPECT II: Introduction to SPECT | CURRENT ISSUES IN QUALITY Assurance II | Scientific Papers: Cardiac | NMTCB: Item Writers Workshop |
| 3:00-3:30 | Visit Exhibits in the EXHIBIT HALL | ALL | | | |
| 3:30-5:00 | ORTHOPEDIC IMAGING III | SPECT III: Advanced SPECT | CURRENT ISSUES IN QUALITY ASSURANCE III | Scientific Papers: PET/Neurology | NMTCB: Item Writers Workshop (continued) |
| JUNE 9 7:00-8:00 | SNM INTRODUCTION • Room 206E | | | | |
| 8:30-10:00 | ONCOLOGY I: A Nuclear Medicine Perspective | CARDIAC I: CAD Pathophysiology, Treatment and Imaging Techniques | TOTAL QUALITY MANAGEMENT | Scientific Papers: Bone/SPECT | ETHICS SEMINAR: A Case Study Approach to Teaching Nuclear Medicine Technology Students |
| 10:00-10:30 | Coffee break in the EXHIBIT HALL, Sponsored by M | HALL, Sponsored by McNeil Pha | cNeil Pharmaceutical | | |
| 10:30-12:00 | ONCOLOGY II: A Nuclear Medicine Perspective | CARDIAC I: CAD Pathophysiology, Treatment and Imaging Techniques (continued) | TOTAL QUALITY MANAGEMENT (continued) | Scientific Papers: Pediatrics/Renal | EDUCATORS FORUM: Current Issues in Educating Nuclear Medicine Technologist |
| 12:00-1:30 | Poster Session in the Exhibit Hall/Visit Exhibits and have lunch | it Exhibits and have lunch in the EXHIBIT HALL | BIT HALL | | JRC FORUM |
| 1:30-3:00 | ONCOLOGY III: A Nuclear Medicine Perspective | CARDIAC II: Alternative Imaging Techniques | TOTAL QUALITY MANAGEMENT (continued) | Scientific Papers: Radiopharmacy | EDUCATORS FORUM: Partnerships Make High Tech/Low Enrollment Programs Possible |
| 3:00-3:30 | Visit Exhibits in the EXHIBIT HALL | HALL | | | |
| 3:30-5:00 | ONCOLOGY IV: A Nuclear Medicine Perspective | CARDIAC II: Alternative Imaging Techniques (continued) | TOTAL QUALITY MANAGEMENT (continued) | Scientific Papers: Radiopharmacy/ Gastroenterology | LEGISLATION AND REGULATIONS IN THE NINETIES |
| JUNE 10 8:30-10:00 | ABDOMINAL AND GENITOURINARY IMAGING I | IMPLEMENTING YOUR NEURO-SPECT Skills I | THE HOW TO'S OF REIMBURSEMENT I | Scientific Papers: Oncology/Infectious Diseases/Endocrinology | ALTERATIONS IN THE BIODISTRIBUTION OF RADIOPHARMACEUTICALS I |
| 10:00-10:30 | Coffee break in the EXHIBIT HALL, Sponsored by M | HALL, Sponsored by McNeil Pha | cNeil Pharmaceutical | | |
| 10:30-12:00 | ABDOMINAL AND GENITOURINARY IMAGING II | IMPLEMENTING YOUR NEURO-SPECT Skills II | THE HOW TO'S OF REIMBURSEMENT II | PRACTICING PET I | ALTERATIONS IN THE BIODISTRIBUTION II |
| 12:00-1:30 | TECHNOLOGIST BUSINESS MEETING & SCIENTIFIC AWARD C | & SCIENTIFIC AWARD CEREMONY | EREMONY ROOMS 206 C&D | | |
| 1:30-3:00 | ABDOMINAL AND GENITOURINARY IMAGING III | IMPLEMENTING YOUR NEURO-SPECT SKILLS III | THE HOW TO'S OF REIMBURSEMENT III | PRACTICING PET II | PEDIATRICS I |
| 3:00-3:30 | | HALL | | | |
| 3:30-5:00 | ABDOMINAL AND GENITOURINARY IMAGING IV | IMPLEMENTING YOUR NEURO-SPECT SKILLS IV | THE HOW TO'S OF REIMBURSEMENT IV | PRACTICING PET III | PEDIATRICS II |
| 8:00-11:00 | Don't Miss the SNM Technologist Party in the Grand Ballroom at the Sheraton | | Centre Hotel and Towers. The Technologist Party is Sponsored by All Exhibitors | ed by All Exhibitors | |
| | | e Con | = Continuing Education = Sci | = Scientific Papers | |

MONDAY YAGSƏUT MEDNESDAY YAGSAUHT

DIRECT RESPONSE

Advertisers for April 1993

Listed below are the companies that have advertised in this issue, as well as those that have been mentioned in the New Products section, simply circle the numbers of those companies you are interested in, fill out the form, and mail or FAX it to The Society of Nuclear Medicine, Marketing Dept., 136 Madison Ave.,

The Journal is testing a new method to enable you to get information on a more

New York, NY 10016. FAX: (212) 545-0221. We will send it to the advertiser. Deadline: July 15, 1993

- **ADAC Laboratories** 1 Milpitas, CA (800) 538-8531 Following Page 8A
- AMR Milford, CT (203) 877-1610 Page 21A
- 12 Biodex Medical Systems Shirley, NY (516) 924-9000 Page 6A
- 23 Capintec, Inc. Ramsey, NJ (800) 631-3826 Page 2A

- 32 Diversified Diagnostic Products, Inc. Houston, TX (713) 955-5323 Page 19A
 - 61 Gammex/RMI Middleton, WI (800) 745-7641 Page 9A
- 124 Medimatic Div. of M.I.D., Inc. New York, NY (212) 688-5620 Back Cover
- 132 Nuclear Fields Des Plaines, IL (800) 932-7203 Page 15A

133 Nuclear Medicine **Consulting Firm** Greenville, PA (800) 682-2226 Page 23A

timely basis from our advertisers.

- 136 Nuclear Cardiology Systems, Inc. Boulder, CO (800) 548-4024 Page 27A
- 181 Siemens Medical Systems, Inc. Hoffman Estates, IL (708) 304-7252 IFC-1A
- 201 UGM Medical Systems, Inc. Philadelphia, PA (215) 222-4999 Inside back cover
- **SNM Meetings** Pages 12A, 16A, 27A, 33A-35A, 41A
- **SNM Membership** Information
- C **SNM Book Order** Information

From:

| Your Name: | Title: | |
|--------------------|-------------------|------|
| Institution: | Dept: | |
| Address: | | |
| City: | State: | Zip: |
| Phone: | FAX: | |
| Primary Specialty: | Secondary Special | tv: |

Circle One Answer In Each Category

Employer

- 1. Hospital
 - a. 500 patients plus
 - b. 300-499 patients
 - c. 200-299 patients
 - d. 100-199 patients
- 2. Private Clinic
- 3. R&D Commercial
- 4. University
- 5. Government
- 6. Other _

Purchase Authority

- 1. Recommend
- 2. Specify
- 3. Purchase

Reason for Inquiry

- 1. Immediate Purchase
- 2. General Information
- 3. Budgeting Information

SNM Member

- 1. Yes
- 2. No

SNM Subscriber

- 1. Yes
- 2. No